Novacyt SA (Paris:ALNOV) (AIM: NCYT), a specialist in clinical diagnostics, announced on Monday the signing by its molecular testing division, Primerdesign Ltd, of an exclusive supply agreement worth a minimum of USD3m with Genesis Diagnostics.
Genesis Diagnostics is a US-based full service diagnostic laboratory that offers clinical diagnostic testing, oral fluid drug testing and services focused on drug monitoring, substance abuse programmes, infectious disease and personalised medicine.
Under this supply agreement, Primerdesign will develop and supply 384 well plate molecular assay panels for respiratory, women's health, sexually transmitted, wound and urinary tract infections for Genesis Diagnostics to use in its clinical service laboratory based in Langhorne, Pennsylvania.
Also, Primerdesign will be appointed the exclusive product manufacturer of the panel for a minimum of five years.
Reportedly, the supply of products under the agreement is expected to commence in early 2019 and Genesis Diagnostics will purchase minimum quantities of product to the value of USD600,000 per year.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review